News | July 11, 2025
Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
The Stryker Mako Robotic System uses artificial intelligence to improve surgical accuracy with real-time guidance, personalized planning, and precise execution
These medicines are essential in preventing RhD immunisation during pregnancy
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Subscribe To Our Newsletter & Stay Updated
